Natalie Finn, Author at BioTuesdays

Developments

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of chronic migraine headache. The double-blind, placebo...

February 6, 2023

Developments

Miromatrix to respond to FDA clinical hold on miroliverELAP in second half

Miromatrix Medical (NASDAQ:MIRO) has evaluated a clinical hold on its investigational miroliverELAP transplantable organ and plans to submit its response to the FDA in the second half of 2023 and initiate a first-in...

February 1, 2023

Developments

Roth Capital acquires MKM Partners

Roth Capital Partners completed its acquisition of MKM Partners on Jan. 31, and the combined organization will conduct business as ROTH MKM. This is the first acquisition ROTH has made in its 30-plus years of business...

February 1, 2023

Developments

First Wave to initiate Phase 2 trial of enhanced adrulipase formulation

First Wave BioPharma (NASDAQ:FWBI) plans to initiate a Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in...

January 31, 2023

Markets

HCW slashes Celularity PT on pipeline priority changes

H.C. Wainwright reduced its price target for Celularity (NASDAQ:CELU) to $2.50 from $15, but reiterated a “buy” rating, after the company unveiled a strategic shift in its pipeline. The stock closed at $1.05 on Jan. 27...

January 30, 2023

Executive Moves

Elucid names Scott Burger as CCO

Elucid, a closely-held medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, appointed Scott Burger as chief commercial officer. His...

January 26, 2023

Developments

Precigen posts positive Phase 1 AdenoVerse data in RRP

Precigen (NASDAQ:PGEN) reported positive Phase 1 dose escalation and expansion cohort data as of the Jan. 12, 2023 cut-off for its investigational PRGN-2012 off-the-shelf AdenoVerse immunotherapy in patients with...

January 25, 2023

Developments

CMS sets national pricing for BioStem’s VENDAJE

The Center for Medicare Services (CMS) established national pricing for BioStem Technologies’ (OTCQB:BSEM) VENDAJE in all Medicare Administrative Contractors (MAC) regions, effective Jan. 1, 2023. VENDAJE allografts now...

January 24, 2023

Markets

AGP drops coverage of Viveve Medical after failed Phase 3 trial

Alliance Global Partners dropped coverage of Vivere Medical (NASDAQ:VIVE) after its pivotal PURSUIT trial in stress urinary incontinence (SUI) in women did not meet its primary endpoint nor several secondary endpoints...

January 23, 2023

Developments

Jazz, Zymeworks post positive Phase 2 survival in metastatic gastroesophageal adenocarcinoma

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) reported the first overall survival (OS) data from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in...

January 19, 2023

Author - Natalie Finn

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

Miromatrix to respond to FDA clinical hold on miroliverELAP in second half

Roth Capital acquires MKM Partners

First Wave to initiate Phase 2 trial of enhanced adrulipase formulation

HCW slashes Celularity PT on pipeline priority changes

Elucid names Scott Burger as CCO

Precigen posts positive Phase 1 AdenoVerse data in RRP

CMS sets national pricing for BioStem’s VENDAJE

AGP drops coverage of Viveve Medical after failed Phase 3 trial

Jazz, Zymeworks post positive Phase 2 survival in metastatic gastroesophageal adenocarcinoma

Subscribe